Boston Convention and Exhibition Center

E Tech Group to Showcase Oligonucleotide Automation Advancements and Deliver Three Informative Presentations at Rockwell Automation Fair 2023

Retrieved on: 
Wednesday, October 25, 2023
Fourth Industrial Revolution, Rockwell, ET, Booth, Automation, TUV, Gold, Research, WEST, Renault Megane E-Tech Electric, Boston Convention and Exhibition Center, Consistency, Convention center, Cloud computing, Rockwell Automation, Information technology, Fine chemical, Northeast Operating Rules Advisory Committee

WEST CHESTER, Ohio, Oct. 25, 2023 /PRNewswire-PRWeb/ -- E Tech Group, a leader in providing high-quality automation, control, and engineering services for industrial clients and Gold Certified Rockwell Automation Partner, today announced the company will be leading three separate presentations at the 2023 Rockwell Automation Fair and exhibiting in booth #232. Automation Fair will take place November 6-9, 2023, in Boston, MA at the Boston Convention and Exhibition Center.

Key Points: 
  • Rockwell Automation Gold Partner E Tech Group to present three educational sessions and demonstrate oligonucleotide automation in booth #232 at Automation Fair in Boston, MA November 6-9, 2023.
  • WEST CHESTER, Ohio, Oct. 25, 2023 /PRNewswire-PRWeb/ -- E Tech Group , a leader in providing high-quality automation, control, and engineering services for industrial clients and Gold Certified Rockwell Automation Partner , today announced the company will be leading three separate presentations at the 2023 Rockwell Automation Fair and exhibiting in booth #232.
  • Automation Fair will take place November 6-9, 2023, in Boston, MA at the Boston Convention and Exhibition Center.
  • As one of the largest Rockwell partners in the life sciences space, E Tech Group is thrilled to be presenting during three different sessions at the 2023 Rockwell Automation Fair showcasing our commitment to innovation and excellence across the industry.

Experts to Discuss Use of AI in Surgery, Impact of Covid-19 on Cancer Screening, STOP THE BLEED® Legislation, and More in Boston Next Week

Retrieved on: 
Thursday, October 19, 2023
Health policy, American College, Life, Student, Legislation, News, Room, American College of Surgeons, Commonwealth, Mentorship, Bleeding, Interview, Artificial intelligence, Boston Convention and Exhibition Center, Medicine, Massachusetts State House, Convention center, ACS, House, COVID-19, Pharmaceutical industry, Tourism, Surgeon

The event will feature a discussion of the application of AI in surgical practice, including in local Boston medical centers.

Key Points: 
  • The event will feature a discussion of the application of AI in surgical practice, including in local Boston medical centers.
  • Representatives from the ACS STOP THE BLEED® program, along with Massachusetts state legislators, will host a news conference on Monday, October 23, 3:00 p.m.
  • ET, in support of recent legislation that would expand lifesaving STOP THE BLEED® kits and training throughout Massachusetts.
  • ET: Students and mentors will learn how to STOP THE BLEED®, which teaches basic bleeding control techniques that can be used to save a life in a bleeding emergency.

Cidara Therapeutics Presents New Preclinical and Clinical Data on Novel Drug-Fc Conjugate CD388 at IDWeek 2023

Retrieved on: 
Wednesday, October 11, 2023
Pharmacokinetics, DFC, SCID, Universal, CDTX, Janssen, Johnson & Johnson, Tavarua, Safety, Drug, Boston Convention and Exhibition Center, Therapy, Doctor of Philosophy, SAN, Janssen Pharmaceuticals, Convention center, Intramuscular injection, Patient, Pharmaceutical industry, Vaccine

SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced new data on its drug-Fc conjugate (DFC) candidate, CD388, at IDWeek 2023.

Key Points: 
  • SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced new data on its drug-Fc conjugate (DFC) candidate, CD388, at IDWeek 2023.
  • The conference is taking place both in-person at the Boston Convention and Exhibition Center in Boston, MA and virtually from October 11 – 15, 2023.
  • “It is important to highlight these new data demonstrating the safety, efficacy and tolerability of CD388 in preventing influenza A and B,” said Jeffrey Stein, Ph.D. president and chief executive officer of Cidara.
  • Janssen recently delivered its Election to Proceed Notice for CD388 with the intent to transfer its rights and obligations to another entity.

Paratek Pharmaceuticals to Present NUZYRA Data at IDWeek 2023

Retrieved on: 
Thursday, October 5, 2023
BCEC, Arthritis, Public, Abstract, Translation studies, Government, Medical Affairs Bureau, Boston Convention and Exhibition Center, Poster, Convention center, Science, Pharmaceutical industry, Nightclub, Skin

BOSTON, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announces that new data from NUZYRA® (omadacycline) scientific and investigator-initiated research programs will be presented at IDWeek 2023.

Key Points: 
  • BOSTON, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announces that new data from NUZYRA® (omadacycline) scientific and investigator-initiated research programs will be presented at IDWeek 2023.
  • The hybrid conference will be held from Oct. 11–15 at the Boston Convention and Exhibition Center.
  • All IDWeek abstracts are embargoed until Oct. 11 at 8:00 a.m.
  • Medical Affairs learning lounge presentation, "CAP in the outpatient setting: Unmet needs and current treatment challenges," featuring guest speaker Teena Chopra, M.D., M.P.H., on Sat., Oct. 14, 10:15–11:00 a.m. in Learning Lounge 2.

Rockwell Automation to Host Annual Investor Meeting

Retrieved on: 
Tuesday, October 3, 2023
Automotive, Packaging, Robotics, Engineering, Technology, Automotive Manufacturing, General Automotive, Manufacturing, Rockwell Automation, Webcast, Convention center, Boston Convention and Exhibition Center, Automation, Growth, Outline, NYSE, Hotel, Management

Rockwell Automation, Inc. (NYSE: ROK) will host its annual investor meeting on Wednesday, Nov. 8, in conjunction with the company’s Automation Fair® being held at the Boston Convention & Exhibition Center in Boston, Massachusetts.

Key Points: 
  • Rockwell Automation, Inc. (NYSE: ROK) will host its annual investor meeting on Wednesday, Nov. 8, in conjunction with the company’s Automation Fair® being held at the Boston Convention & Exhibition Center in Boston, Massachusetts.
  • The public webcast portion of the meeting will begin at approximately 10:10 a.m.
  • The presentation will outline Rockwell’s long-term business strategy, including key areas of growth and longer-term financial targets.
  • The webcast will be available on the Rockwell Automation Investor Relations website at www.rockwellautomation.com/en-us/investors.html .

BostonGene to Present Unique AI-Driven Bioinformatic Solutions at the Festival of Genomics & Biodata

Retrieved on: 
Monday, October 2, 2023
Biotechnology, Technology, Health, Pharmaceutical, Biometrics, Health Technology, Other Science, Research, Artificial Intelligence, Genetics, Science, Festival, Boston Convention and Exhibition Center, Genomics, Pharmaceutical industry

BostonGene will also exhibit at booth 17.

Key Points: 
  • BostonGene will also exhibit at booth 17.
  • BostonGene session details are below:
    In this session, BostonGene will discuss how advances in next-generation sequencing have generated a wealth of unmined genomic data across myriad fields, including oncology.
  • The presentation will cover comprehensive solutions that combine high-complexity bioinformatics, large throughput molecular and genomic CLIA/CAP technologies, and several large-scale databases to support early and late discovery projects.
  • To learn more or to schedule a meeting with BostonGene during the event, please contact Maria Proia at [email protected] .

Cidara Therapeutics to Present New Data on Novel drug-Fc conjugate CD388 at IDWeek 2023

Retrieved on: 
Wednesday, September 27, 2023
Drug, SCID, Intramuscular injection, Boston Convention and Exhibition Center, Janssen, CDTX, Janssen Pharmaceuticals, DFC, Patient, Pharmacokinetics, SAN, Convention center, Johnson & Johnson, Universal, Therapy, Pharmaceutical industry, Vaccine

SAN DIEGO, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that it will present new data on its drug-Fc conjugate (DFC) candidate, CD388, in an oral presentation and two poster presentations at IDWeek 2023.

Key Points: 
  • SAN DIEGO, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that it will present new data on its drug-Fc conjugate (DFC) candidate, CD388, in an oral presentation and two poster presentations at IDWeek 2023.
  • The conference will take place both in-person at the Boston Convention and Exhibition Center in Boston, MA and virtually from October 11 – 15, 2023.
  • CD388 is being developed for the universal protection of influenza A and B under an exclusive worldwide collaboration agreement with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson company.
  • Janssen recently delivered its Election to Proceed Notice for CD388 with the intent to transfer its rights and obligations to another entity.

PhenomeX Unveils Meteor™ Chips For Quantitative Bulk Analysis On The IsoSpark™ Platform To Revolutionize High Throughput Multiplexed Hands-Free Proteomics

Retrieved on: 
Friday, September 15, 2023
Drug development, Booth, Boston Convention and Exhibition Center, Proteomics, Metabolomics, Research, ELISA, Data analysis, CELL, Convention center, Bioprocess, Meteoroid, Retail

EMERYVILLE, Calif., Sept. 15, 2023 /PRNewswire/ -- PhenomeX Inc. (Nasdaq: CELL), the functional cell biology company, today announced the launch of Meteor™ chips on the IsoSpark™ platform, providing a significant advancement in high throughput, quantitative, fully automated, multiplexed bulk proteomics. ™

Key Points: 
  • ™
    The Meteor chip solution enables researchers to conduct high throughput proteomic analysis with unmatched efficiency.
  • Quantitative analysis: Each run incorporates recombinant standards run in triplicate, enabling quantitative analysis per chip on-site.
  • PhenomeX representatives will be available to provide demonstrations and discuss how the Meteor solution can revolutionize proteomics research and accelerate scientific advancements.
  • For more information about the Meteor solution on the IsoSpark platform, please visit the PhenomeX website at https://phenomex.com/products/chips/meteor/ .

Dyadic to Present at BioProcess International

Retrieved on: 
Tuesday, September 12, 2023
Convention center, Boston Convention and Exhibition Center, Food, Fine chemical

JUPITER, Fla., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that Joseph Hazelton, Chief Business Officer of Dyadic will be presenting at BioProcess International.

Key Points: 
  • JUPITER, Fla., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that Joseph Hazelton, Chief Business Officer of Dyadic will be presenting at BioProcess International.
  • BioProcess International , September 19-21, 2023
    Boston Convention and Exhibition Center, Boston, MA
    If you would like to connect with Dyadic at this event, you may request a one-on-one meeting at [email protected] or you can connect online through the partnering portal provided upon registration to the event.

Rockwell Automation Opens Registration for all-new Automation Fair®

Retrieved on: 
Thursday, September 14, 2023
Packaging, Automotive, General Automotive, Automotive Manufacturing, Manufacturing, Other Manufacturing, Learning, Industrial internet of things, Körber Process Solutions, Possibility, ARMI, Boston Convention and Exhibition Center, Powerplex STL, Automation, Movement, Food, ICT, Motion, Rockwell Automation, Convention center, ESG, Social, OEM, NYSE, Sales, Tourism, Video game

Rockwell Automation, Inc. (NYSE: ROK), the world’s largest company dedicated to industrial automation and digital transformation, is pleased to announce that registration for Automation Fair 2023 is officially open, hosted by Rockwell and members of its global PartnerNetwork™ program.

Key Points: 
  • Rockwell Automation, Inc. (NYSE: ROK), the world’s largest company dedicated to industrial automation and digital transformation, is pleased to announce that registration for Automation Fair 2023 is officially open, hosted by Rockwell and members of its global PartnerNetwork™ program.
  • More than 325 sessions will be delivered by experts from Rockwell, its partners, and its customers to help attendees move their manufacturing journey forward.
  • Attendees are invited to witness cutting-edge technology showcasing Rockwell and partner solutions in real-world applications during the first two days of Automation Fair, Nov. 6 and 7.
  • Registration for Automation Fair is now open , with early registration rates available until September 30.